Company Overview: GILD

GILD Overview

Upcoming Projects (GILD)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (GILD)

Discussing BTK inhibitors in autoimmune indications
Tickers: NVS, BMY, GILD, SNY
Executed On: Oct 01, 2024 at 01:30 PM EDT
A Second Opinion: An updated look at Gilead's interim results from the ongoing ASSURE study of seladelpar for Primary Biliary Cholangitis
Ticker: GILD
Executed On: Jun 07, 2024 at 03:30 PM EDT
An updated look at Gilead's interim results from the ongoing ASSURE study of seladelpar for Primary Biliary Cholangitis
Ticker: GILD
Executed On: Jun 07, 2024 at 11:00 AM EDT
Digging into Gilead's Trodelvy (sacituzimab govitecan-hziy) after FDA approval in pre-treated HR+/HER2- metastatic breast cancer
Ticker: GILD
Executed On: Mar 07, 2023 at 04:00 PM EST
Discussing the recent Phase 3 TROPiCS-02 data on Trodelvy in HR+/HER2- metastatic breast cancer presented at ESMO 2022
Ticker: GILD
Executed On: Sep 22, 2022 at 10:00 AM EDT
Discussion of current NHL CAR-T and outlook for allogeneic therapies in DLBCL
Tickers: BMY, GILD, NVS, CRSP, ALLO, ACET
Executed On: May 03, 2022 at 01:00 PM EDT

Expired Projects (GILD)

Discussing Gilead’s Trodelvy for the treatment of HR+/HER2- Metastatic Breast Cancer, Following EMA Approval; PDUFA due February
Ticker: GILD
Execute By: Feb 28, 2023
A Second View: Exploring the potential of FGEN's Pamrevlumab, GLPG1690 and BG00011 in Idiopathic Pulmonary Fibrosis
Tickers: FGEN, GLPG, GILD, BIIB
Execute By: Sep 27, 2019

Upcoming & Overdue Catalysts (GILD)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (GILD)

Additional Data Released on Gilead's (GILD) Investigational Antiviral Remdesivir for the Treatment of COVID-19
Ticker: GILD
Occurred on: Jul 10, 2020
Topline Results Released From Gilead's (GILD) Phase 2 ATLAS Study of cilofexor 30 mg, firsocostat 20 mg and selonsertib 18 mg in Patients With Bridging Fibrosis and Compensated Cirrhosis Due to NASH
Ticker: GILD
Occurred on: Dec 16, 2019
Phase 2 study of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the treatment of Chronic HBV to complete June 2018
Tickers: GILD, GBIM
Occurred on: Jun 15, 2018
Gilead Sciences (GILD) plan to fully enroll Phase 3 STELLAR trial for nonalcoholic steatohepatitis (NASH) evaluating selonsertib in treating F3 fibrosis by first half of 2018
Ticker: GILD
Occurred on: Apr 13, 2018
Gilead Sciences (GILD) plans to fully enroll Phase 3 STELLAR 4 trial for nonalcoholic steatohepatitis (NASH) evaluating selonsertib in treating F4 cirrhosis
Ticker: GILD
Occurred on: Feb 23, 2018
Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV PDUFA set to February 12, 2018
Ticker: GILD
Occurred on: Feb 07, 2018
Gilead(GILD)'s Yescarta (Axicabtagene Ciloleucel) First CAR T Therapy Approved by the FDA for the Treatment of Adult Patients With Relapsed or Refractory Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy
Tickers: GILD, KITE
Occurred on: Oct 18, 2017
FDA Approves Expanded Labeling for Epclusa (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV
Ticker: GILD
Occurred on: Aug 01, 2017
Gilead (GILD) Announces Phase 3 Results for Investigational Fixed-Dose Combination of Bictegravir, Emtricitabine and Tenofovir Alafenamide for Treatment of HIV
Ticker: GILD
Occurred on: Jul 24, 2017
FDA approves Gilead Sciences (GILD) Vosevi for the treatment of HCV genotypes 1 through 6
Ticker: GILD
Occurred on: Jul 18, 2017
Gilead (GILD) Plans to Submit Marketing Authorization Application (MAA) to European Commission for Bictegravir (B/F/TAF) Single Tablet HIV-1 Infection Regimen in Q3 2017
Ticker: GILD
Occurred on: Jul 13, 2017
Gilead (GILD) Expects to Submit New Drug Application for HIV-1 Infection Single Tablet Regimen Bictegravir (B/F/TAF) to FDA in Q3 2017
Ticker: GILD
Occurred on: Jun 12, 2017
Gilead (GILD) Expects Phase 3 Data Evaluating Bictegravir Single-Tablet Regimen (B/F/TAF) in Combination with Tenofovir Alafenamide (TAF) and Emtricitabine (FTC) for the Treatment of HIV-1 infection in Mid 2017
Ticker: GILD
Occurred on: May 30, 2017
Gilead (GILD) Expects to Release Futility Analysis in Q3 2017 From Phase 3 Trial Evaluating GS-5745 in Gastric Cancer
Ticker: GILD
Occurred on: May 30, 2017
Gilead (GILD) Presents Data from Open-Label Proof-of-Concept Study Evaluating GS-0976 in Non-Alcoholic Steatohepatitis (NASH)
Ticker: GILD
Occurred on: Apr 21, 2017
Gilead Begins Phase 3 Study of Eleclazine for Treatment of Long QT-3 Syndrome - Data Readout Expected H1 of 2017 - Terminated
Ticker: GILD
Occurred on: Feb 24, 2017
Gilead (GILD) Presents 48-Week Phase 2 Data Evaluating HIV-1 Infection Regimen Bictegravir (B/F/TAF) in Combination with Dolutegravir at the Annual Conference on Retroviruses and Opportunistic Infections (CROI)
Ticker: GILD
Occurred on: Feb 13, 2017
Gilead (GILD) Plans European Regulatory Application in Early 2017 for Sofosbuvir/Velpatasvir/Voxilaprevir in Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients
Ticker: GILD
Occurred on: Jan 20, 2017
European Commission Expected to Make Final Decision in ~60 Days on Gilead's (GILD) Vemlidy in Adults with Chronic HBV Infection
Ticker: GILD
Occurred on: Jan 11, 2017
Gilead (GILD) Initiates Dosing in Phase 2b/3 SELECTION Trial Evaluating Filgotinib in Moderately to Severely Active Ulcerative Colitis
Ticker: GILD
Occurred on: Dec 12, 2016
Gilead (GILD) Plans to Submit FDA Application for Sofosbuvir/Velpatasvir/Voxilaprevir in Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients by End of 2016
Ticker: GILD
Occurred on: Dec 08, 2016
Janssen (JNJ) Initiates Phase 2b Study Evaluating Simeprevir/Odalasvir/JNJ-4178 in Chronic Hepatitis C Virus Infection Genotypes 1,2,4,5 and 6 Without Cirrhosis
Tickers: JNJ, GILD, ABBV
Occurred on: Nov 28, 2016
Gilead (GILD) Announces Top-Line Results From Two Phase 3 Studies Evaluating Momelotinib for Patients With Myelofibrosis
Ticker: GILD
Occurred on: Nov 16, 2016
PDUFA date for TAF NDA in HBeAg and HBeAG+ chronic HBV infection set for Nov 11 2016
Ticker: GILD
Occurred on: Nov 10, 2016
Gilead (GILD) Releases Data From Four Phase 3 POLARIS Studies Evaluating Sofosbuvir/Velpatasvir/Voxilaprevir in Treatment-Experienced Genotype 1-6 Chronic HCV-Infected Patients
Ticker: GILD
Occurred on: Oct 20, 2016
Phase II simtuzumab HVPG cirrhosis data in portal hypertension expected near year end of 2016
Ticker: GILD
Occurred on: Oct 20, 2016
Gilead (GILD) Announces Top-Line Phase 2 Data for GS-4997 in Nonalcoholic Steatohepatitis (NASH)
Ticker: GILD
Occurred on: Oct 20, 2016
Gilead (GILD) Announces Top-Line Phase 2 Data for GS-4997 in Diabetic Kidney Disease (DKD)
Ticker: GILD
Occurred on: Oct 20, 2016
ContraVir (CTRV) Announces Positive Recommendation from Independent Data Safety Monitoring Board to Proceed to Phase 2a Testing Comparing CMX157 to Gilead's (GILD) Viread in Chronic Hepatitis B (HBV) Infection
Tickers: CTRV, GILD
Occurred on: Oct 17, 2016
2nd Presidential Debate between Donald Trump and Hillary Clinton at Washington University in St. Louis, Missouri from 9 p.m. EDT to 10:30 p.m. EDT
Tickers: VRX, PFE, MYL, Turing Pharmaceuticals, GILD
Occurred on: Oct 09, 2016
FDA Announces Black Box Requirement for Risk of HBV Reactivation for at Least 9 Brand Name Drugs in Hepatitis C Treatment
Tickers: GILD, ABBV, MRK
Occurred on: Oct 05, 2016
First Presidential debate between Donald Trump and Hillary Clinton at Hofstra University, New York, from 9 p.m. EDT to 10:30 p.m. EDT
Tickers: VRX, PFE, GILD, MYL
Occurred on: Sep 26, 2016
Gilead Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerative Colitis
Ticker: GILD
Occurred on: Sep 21, 2016
European Commission Grants Marketing Authorization for Gilead’s Once-Daily Truvada For Reducing the Risk of Sexually Acquired HIV-1
Ticker: GILD
Occurred on: Aug 22, 2016
European CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada for Reducing the Risk of Sexually Acquired HIV
Ticker: GILD
Occurred on: Jul 22, 2016
Gilead’s Odefsey (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) Meets Primary 48-Week Objective in Two Phase 3b Studies
Ticker: GILD
Occurred on: Jul 21, 2016
European Commission Grants Marketing Authorization for Gilead’s Single Tablet Regimen Odefsey (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV
Ticker: GILD
Occurred on: Jun 23, 2016
Gilead escapes liability in hepatitis C patent fight
Ticker: GILD
Occurred on: Jun 06, 2016
European CHMP Adopts Positive Opinion for Gilead’s Epclusa (Sofosbuvir/Velpatasvir) for the Treatment of All Genotypes of Chronic Hepatitis C
Ticker: GILD
Occurred on: May 27, 2016
Gilead Sciences Announces Appointment of Kevin Young CBE as Chief Operating Officer and Martin Silverstein, MD as Executive Vice President, Strategy
Ticker: GILD
Occurred on: May 24, 2016
PDUFA Date for F/TAF for Treatment of HIV set for April 7, 2016
Ticker: GILD
Occurred on: Apr 04, 2016
Gilead Submits New Drug Application to Japan’s Pharmaceutical and Medical Devices Agency for Tenofovir Alafenamide (TAF) for Patients with Chronic Hepatitis B Infection
Ticker: GILD
Occurred on: Mar 31, 2016
FDA Approves Odefsey for Treatment of HIV-1
Tickers: GILD, JNJ
Occurred on: Mar 01, 2016
U.S. Food and Drug Administration Approves Gilead’s Second TAF-Based Single Tablet Regimen Odefsey (Emtricitabine, Rilpivirine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection
Ticker: GILD
Occurred on: Mar 01, 2016
Gilead Announces CHMP Adopts Positive Opinion on Duscovy for Treatment of HIV
Ticker: GILD
Occurred on: Feb 26, 2016
Gilead Submits New Drug Application to U.S. Food and Drug Administration for Tenofovir Alafenamide (TAF) for the Treatment of Chronic Hepatitis B
Ticker: GILD
Occurred on: Feb 25, 2016
US FDA Approves Two Supplemental Indications for Harvoni in Chronic Hepatitis C Patients With Advanced Liver Disease
Ticker: GILD
Occurred on: Feb 16, 2016
U.S. FDA Approves Two Supplemental Indications for Harvoni in Chronic Hepatitis C Patients With Advanced Liver Disease
Ticker: GILD
Occurred on: Feb 16, 2016
Gilead's board of directors approved the repurchase of an additional $12 billion of the company’s common stock to commence upon completion of the company’s existing $15 billion repurchase program authorized in January 2015
Ticker: GILD
Occurred on: Feb 02, 2016
Effective March 10, Gilead Sciences Chairman and CEO John Martin, Ph.D. will transition to the role of Executive Chairman, and President & COO John Milligan, Ph.D. will be promoted to CEO.
Ticker: GILD
Occurred on: Jan 29, 2016
Merck Recieves FDA approval of ZEPATIER (elbasvirand grazoprevir) for the treatment of chronic Hepatitis C Virus genotype 1 or 4 infection in adults following priority review; the new therapy will cost $54,600 for a 12-week regimen
Tickers: MRK, GILD
Occurred on: Jan 28, 2016
Grazoprevir/Elbasvir for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection Company Granted FDA Priority Review with Target Action Date of January 28, 2016
Tickers: MRK, GILD
Occurred on: Jan 28, 2016
Gilead has increased its stake in Galapagos to 45,837,043 shares or 14.75%, crossing a 10% threshold of GLPG's voting rights
Tickers: GILD, GLPG
Occurred on: Jan 25, 2016
Galapagos inks $2.1B deal with Gilead to develop filgotinib for inflammatory conditions
Tickers: GLPG, GILD
Occurred on: Dec 17, 2015
Bristol-Myers Squibb (BMY) to Present Data from Several Studies on Hepatitis C Patients at Annual Meeting of The American Association for the Study of Liver Diseases 2015
Tickers: BMY, GILD, ABBV
Occurred on: Nov 17, 2015
FDA Approves Gilead's (GILD) Single Tablet Regimen Genvoya for Treatment of HIV-1 Infection
Ticker: GILD
Occurred on: Nov 05, 2015
Bristol-Myers Squibb (BMY) Announces Complete Phase 2a Proof-of-Concept Study of BMS-955176 in Treatment of HIV-1
Tickers: BMY, GILD
Occurred on: Oct 23, 2015

Strategic Initiatives (GILD)

Gilead Sciences (GILD) to Acquire Immunomedics (IMMU)
Tickers: GILD, IMMU
Announcement Date: Sep 13, 2020
Gilead Sciences (GILD) and Tango Therapeutics to Expand Strategic Oncology Collaboration
Ticker: GILD
Announcement Date: Aug 17, 2020
DURECT (DRRX) and Gilead (GILD) Enter into License Agreement for Long-Acting Injectable HIV Investigational Product
Tickers: DRRX, GILD
Announcement Date: Jul 22, 2019
Gilead(GILD) and Galapagos(GLPG) Enter Collaboration
Tickers: GLPG, GILD
Announcement Date: Jul 14, 2019
Alpine Immune Sciences (ALPN) discloses that Gilead Sciences' (GILD) Kite Pharma will terminate their October 2015 license and research agreement aimed at developing protein-based immunotherapies for cancer effective June 20
Tickers: ALPN, GILD
Announcement Date: May 24, 2019
Gilead Sciences and Precision BioSciences Announce Collaboration to Develop Therapies Against Hepatitis B Virus Using ARCUS Genome Editing
Tickers: GILD, Precision BioSciences
Announcement Date: Sep 12, 2018
Merck Discontinues MK-3682B and MK-3682C Development Programs
Tickers: MRK, GILD
Announcement Date: Sep 29, 2017
Gilead Sciences (GILD) to Acquire Kite Pharma (KITE) for $11.9 Billion
Tickers: GILD, KITE
Announcement Date: Aug 28, 2017
Amygdala Neurosciences Licenses Substance Abuse Candidate GS-6637 from Gilead (GILD) for Undisclosed Sum
Tickers: GILD, Amygdala Neurosciences
Announcement Date: Feb 16, 2017
Gilead Sciences Announces Acquisition of Nimbus Therapeutics’ Acetyl-CoA Carboxlyase (ACC) Program for NASH and Other Liver Diseases for $1.2B
Tickers: GILD, Nimbus Therapeutics
Announcement Date: Apr 04, 2016